Autolus Therapeutics plc (AUTL) Fair Value 2026

AUTL · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

5.6 /10

32 fundamental signals · 1 models active

Value Trap Risk

LOW (28/100)

Quick Summary — As of 2026-08-28, Autolus Therapeutics plc (AUTL) trades at $2.34. QOC: 5.6/10. Value Trap Risk: 28/100 (LOW). 1/13 models active.

Key Facts

Ticker
AUTL
Price
$2.34
Quality Score
5.6/10
Value Trap Risk
28/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give AUTL?

1 Intrinsic Value Models vs. Current Price ($2.34)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $1.16 -50.4%

All Models Active

All 1 models are displayed above.

What Is Autolus Therapeutics plc (AUTL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Autolus Therapeutics plc's intrinsic value is estimated at $1.16. Trading at its current price of $2.34, the valuation engine raises significant caution: 1 of 1 models flag downside risk, projecting a median implied return of -50.4%.

What Do the Models Say About AUTL?

1 of 13 models are currently active for AUTL. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does AUTL Rank in Biotechnology?

Among 625 Biotechnology stocks, AUTL ranks #198 by Quality of Company score. CirclFi's QOC score of 5.6/10 evaluates 32 fundamental signals. A score of 5.6 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

Autolus Therapeutics plc's positioning within the Biotechnology segment means that market exclusivity window plays an outsized role in fundamental analysis. The sector's unique characteristics — including platform technology validation — shape both the opportunity set and risk profile.

Is AUTL a Value Trap?

CirclFi's Value Trap algorithm assigns AUTL a score of 28/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Autolus Therapeutics plc. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, Autolus Therapeutics plc earns a quality score of 5.6/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every AUTL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across AUTL's 1 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Autolus Therapeutics plc Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

UPBUpstream Bio, Inc.QOC 5.6CYCNCyclerion Therapeutics, Inc.QOC 5.6ROIVRoivant Sciences Ltd.QOC 5.6FATEFate Therapeutics, Inc.QOC 5.6IVAInventiva S.A.QOC 5.6ALTAltimmune, Inc.QOC 5.6PVCTProvectus Biopharmaceuticals, Inc.QOC 4.9ARTLArtelo Biosciences, Inc.QOC 4.2ARCTArcturus Therapeutics Holdings Inc.QOC 7.2EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: UPB · CYCN · ROIV · FATE · IVA · ALT · PVCT · ARTL · ARCT · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to AUTL?

7 companies across all industries closest to AUTL’s Quality of Company score of 5.6/10.

MOVECorvex, Inc.QOC 5.6GLOOGloo Holdings, Inc.QOC 5.6BSINBig Sky Industrial Inc.QOC 5.6CGBDCarlyle Secured Lending, Inc.QOC 5.6ACREAres Commercial Real Estate CorporationQOC 5.6ABATAmerican Battery Technology CompanyQOC 5.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: MOVE · GLOO · BSIN · CGBD · ACRE · ABAT · NVDA

Where Does AUTL Sit in CirclFi's Biotechnology Rankings?

AUTL is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Autolus Therapeutics plc’s Valuation?

What is Autolus Therapeutics plc's intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Autolus Therapeutics plc (AUTL). The Quality of Company score is 5.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is AUTL overvalued or undervalued right now?

At $2.34, 0 of 1 active models suggest AUTL may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Autolus Therapeutics plc's business model in Biotechnology.

What does a Quality of Company score of 5.6 mean for AUTL?

Autolus Therapeutics plc's QOC of 5.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on AUTL?

CirclFi analyzes AUTL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is AUTL a value trap in 2026?

Autolus Therapeutics plc's Value Trap score is 28/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Autolus Therapeutics plc (AUTL) a Quality of Company score of 5.6/10 across 32 fundamental signals as of 2026-08-28.” Source: circlfi.com/stock/AUTL/ · Methodology
Primary sources for this AUTL valuation
  • Financial statements: Autolus Therapeutics plc 10-K and 10-Q filings on SEC EDGAR (CIK 0001730463) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for AUTL as of ; valuations recomputed .